Last updated on April 23, 2014 at 13:21 EDT

Latest RuiYi Stories

2012-10-04 02:26:24

LA JOLLA, Calif., BREDA, Netherlands and GHENT, Belgium, Oct. 4, 2012 /PRNewswire/ -- RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the...

2012-10-04 02:26:19

LA JOLLA, Calif. and SHANGHAI, Oct. 4, 2012 /PRNewswire/ -- Anaphore announced today that its corporate name has changed to RuiYi. As part of the company's shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai. "RuiYi's new direction will enable us to focus on building our capabilities in...